Frequency and prognostic role of mucosal healing in patients with Crohn's disease and ulcerative colitis after one-year of biological therapy

Klaudia Farkas, Péter László Lakatos, Mónika Szucs, Éva Pallagi-Kunstár, Anita Bálint, Ferenc Nagy, Zoltán Szepes, Noémi Vass, Lajos S. Kiss, Tibor Wittmann, Tamás Molnár

Research output: Article

24 Citations (Scopus)

Abstract

Aim: To assess the endoscopic activity before and after a one-year period of biological therapy and to evaluate the frequency of relapses and need for retreatment after stopping the biologicals in patients with Crohn's disease (CD) and ulcerative colitis (UC). Methods: The data from 41 patients with CD and 22 patients with UC were assessed. Twenty-four CD patients received infliximab, and 17 received adalimumab. The endoscopic severity of CD was quantified with the simplified endoscopic activity score for Crohn's disease in CD and with the Mayo endoscopic subscore in UC. Results: Mucosal healing was achieved in 23 CD and 7 UC patients. Biological therapy had to be restarted in 78% of patients achieving complete mucosal healing with CD and in 100% of patients with UC. Neither clinical remission nor mucosal healing was associated with the time to restarting the biological therapy in either CD or UC. Conclusion: Mucosal healing did not predict sustained clinical remission in patients in whom the biological therapies had been stopped.

Original languageEnglish
Pages (from-to)2995-3001
Number of pages7
JournalWorld journal of gastroenterology
Volume20
Issue number11
DOIs
Publication statusPublished - márc. 2014

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Frequency and prognostic role of mucosal healing in patients with Crohn's disease and ulcerative colitis after one-year of biological therapy'. Together they form a unique fingerprint.

  • Cite this